Postmenopausal Estrogen/Progestin Interventions (PEPI) Identifier:
First received: October 27, 1999
Last updated: July 20, 2005
Last verified: July 2005

To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.

Condition Intervention Phase
Bone Diseases
Cardiovascular Diseases
Coronary Disease
Diabetes Mellitus
Heart Diseases
Myocardial Ischemia
Drug: estrogens, conjugated
Drug: medroxyprogesterone
Drug: progesterone
Drug: estrogen replacement therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: September 1987
Estimated Study Completion Date: October 2000
  Show Detailed Description


Ages Eligible for Study:   45 Years to 64 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Postmenopausal women, ages 45 to 64. One third of the subjects had had a hysterectomy.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000466

Sponsors and Collaborators
Investigator: Mark Espeland Bowman Gray School of Medicine
  More Information

National Heart , Lung and Blood Institute. Hormone replacement therapy and heart disease: The PEPI trial. DHHS. NIH Publication No.95-3277. August 1995 Identifier: NCT00000466     History of Changes
Other Study ID Numbers: 55
Study First Received: October 27, 1999
Last Updated: July 20, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Bone Diseases
Cardiovascular Diseases
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Heart Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Musculoskeletal Diseases
Vascular Diseases
Estrogens, Conjugated (USP)
Medroxyprogesterone Acetate
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Contraceptive Agents
Contraceptive Agents, Female
Contraceptive Agents, Male
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs processed this record on September 03, 2015